Ticagrelor: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOEDITSECTION____NOTOC__ | __NOEDITSECTION____NOTOC__ | ||
{{CMG}} {{AE}}{{JH}} | {{CMG}} {{AE}} {{JH}} | ||
{{SB}} [[Brilinta]] | {{SB}} [[Brilinta]] | ||
Revision as of 19:26, 28 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Synonyms / Brand Names: Brilinta
Overview
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.[1][2] The drug was approved by the US Food and Drug Administration on July 20, 2011.[3]
Category
P2Y12 platelet inhibitor, platelet aggregation inhibitor
Prescribing Information
Brilinta (ticagrelor) tablet
References
- ↑ "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.
- ↑ European Public Assessment Report Possia
- ↑ "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes". FDA. 20 July 2011.